Ventyx Biosciences, Inc. (VTYX) has disclosed a new risk, in the Supply Chain category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ventyx Biosciences, Inc. is significantly exposed to various risks due to its reliance on suppliers in China for manufacturing and non-clinical research. The company faces potential challenges from economic, political, and legal changes within China, including trade tensions with the United States, regulatory uncertainties, and intellectual property concerns. The Chinese biopharmaceutical sector’s strict regulations and potential changes in policies could affect the company’s operations and financial condition. Additionally, proposed U.S. legislation like the BIOSECURE Act could further impact Ventyx’s supply chain and increase costs, potentially delaying clinical development programs.
Overall, Wall Street has a Moderate Buy consensus rating on VTYX stock based on 1 Buy and 1 Hold.
To learn more about Ventyx Biosciences, Inc.’s risk factors, click here.